Apellis Pharmaceuticals Current Valuation
| APLS Stock | USD 22.31 0.27 1.20% |
Valuation analysis of Apellis Pharmaceuticals helps investors to measure Apellis Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to gain to -28.37 in 2026. Enterprise Value Multiple is likely to gain to -28.37 in 2026. Fundamental drivers impacting Apellis Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Apellis Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Apellis Pharmaceuticals is based on 3 months time horizon. Increasing Apellis Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apellis stock is determined by what a typical buyer is willing to pay for full or partial control of Apellis Pharmaceuticals. Since Apellis Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apellis Stock. However, Apellis Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.31 | Real 28.39 | Target 33.95 | Hype 22.3 |
The intrinsic value of Apellis Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apellis Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apellis Pharmaceuticals helps investors to forecast how Apellis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apellis Pharmaceuticals more accurately as focusing exclusively on Apellis Pharmaceuticals' fundamentals will not take into account other important factors: Apellis Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Apellis Stock properly, considering its historical fundamentals such as Current Valuation. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Apellis introduce new products? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.35 | Revenue Per Share | Quarterly Revenue Growth 1.33 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apellis Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apellis Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apellis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Apellis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apellis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apellis Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Apellis Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Apellis Pharmaceuticals or generate 0.0% return on investment in Apellis Pharmaceuticals over 90 days. Apellis Pharmaceuticals is related to or competes with Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, and Ideaya Biosciences. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apellis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apellis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.67 | |||
| Information Ratio | 0.0417 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 |
Apellis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apellis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apellis Pharmaceuticals historical prices to predict the future Apellis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.064 | |||
| Jensen Alpha | 0.1747 | |||
| Total Risk Alpha | (0.18) | |||
| Sortino Ratio | 0.0401 | |||
| Treynor Ratio | 0.34 |
Apellis Pharmaceuticals February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.064 | |||
| Market Risk Adjusted Performance | 0.35 | |||
| Mean Deviation | 2.51 | |||
| Semi Deviation | 3.58 | |||
| Downside Deviation | 3.67 | |||
| Coefficient Of Variation | 1409.05 | |||
| Standard Deviation | 3.53 | |||
| Variance | 12.49 | |||
| Information Ratio | 0.0417 | |||
| Jensen Alpha | 0.1747 | |||
| Total Risk Alpha | (0.18) | |||
| Sortino Ratio | 0.0401 | |||
| Treynor Ratio | 0.34 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 | |||
| Downside Variance | 13.5 | |||
| Semi Variance | 12.82 | |||
| Expected Short fall | (2.76) | |||
| Skewness | (0.90) | |||
| Kurtosis | 5.2 |
Apellis Pharmaceuticals Backtested Returns
Apellis Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0609, which signifies that the company had a 0.0609 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Apellis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Apellis Pharmaceuticals' mean deviation of 2.51, and Risk Adjusted Performance of 0.064 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apellis Pharmaceuticals holds a performance score of 4. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. Please check Apellis Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Apellis Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.45 |
Modest reverse predictability
Apellis Pharmaceuticals has modest reverse predictability. Overlapping area represents the amount of predictability between Apellis Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apellis Pharmaceuticals price movement. The serial correlation of -0.45 indicates that just about 45.0% of current Apellis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.45 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 3.65 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Apellis Pharmaceuticals has a Current Valuation of 2.82 B. This is 80.38% lower than that of the Biotechnology sector and 39.34% lower than that of the Health Care industry. The current valuation for all United States stocks is 83.05% higher than that of the company.
Apellis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Apellis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Apellis Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0513 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 2.82 B | ||||
| Shares Outstanding | 126.53 M | ||||
| Shares Owned By Insiders | 13.93 % | ||||
| Shares Owned By Institutions | 86.07 % | ||||
| Number Of Shares Shorted | 21.24 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 7.03 X | ||||
| Price To Sales | 2.78 X | ||||
| Revenue | 781.37 M | ||||
| Gross Profit | 605.05 M | ||||
| EBITDA | (154.53 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 3.17 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Short Ratio | 5.64 X | ||||
| Earnings Per Share | 0.35 X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 33.95 | ||||
| Number Of Employees | 705 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 2.82 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 885.05 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.